Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies.
Biomarkers, cancer
Doxorubicin
Lipiodol
Liver cancer
Pharmacokinetics
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
08
07
2020
accepted:
06
10
2020
revised:
19
08
2020
pubmed:
17
10
2020
medline:
16
4
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
To evaluate the prognostic potential of Lipiodol distribution for the pharmacokinetic (PK) profiles of doxorubicin (DOX) and doxorubicinol (DOXOL) after conventional transarterial chemoembolization (cTACE). This prospective clinical trial ( ClinicalTrials.gov : NCT02753881) included 30 consecutive participants with liver malignancies treated with cTACE (5/2016-10/2018) using 50 mg DOX/10 mg mitomycin C emulsified 1:2 with ethiodized oil (Lipiodol). Peripheral blood was sampled at 10 timepoints for standard non-compartmental analysis of peak concentrations (C Hepatocellular (n = 26), cholangiocarcinoma (n = 1), and neuroendocrine metastases (n = 3) were included. Stratified according to Lipiodol distribution, DOX-C This prospective clinical trial provides updated PK data revealing Lipiodol distribution as an imaging marker predictive of DOX-C • Prospective pharmacokinetic analysis after conventional TACE revealed Lipiodol distribution (1 vs. ≥ 2 segments vs. lobar) as an imaging marker predictive of doxorubicin peak concentrations (C
Identifiants
pubmed: 33063185
doi: 10.1007/s00330-020-07380-w
pii: 10.1007/s00330-020-07380-w
doi:
Substances chimiques
Ethiodized Oil
8008-53-5
Doxorubicin
80168379AG
Banques de données
ClinicalTrials.gov
['NCT02753881']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3002-3014Subventions
Organisme : Guerbet
ID : Institutional Study Grant
Références
Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF (2016) Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 64(1):106–116
doi: 10.1002/hep.28453
European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 69(1):182–236
doi: 10.1016/j.jhep.2018.03.019
Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68(2):723–750
doi: 10.1002/hep.29913
Kiefer MV, Albert M, McNally M et al (2011) Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 117(7):1498–1505
doi: 10.1002/cncr.25625
Albert M, Kiefer MV, Sun W et al (2011) Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 117(2):343–352
doi: 10.1002/cncr.25387
de Baere T, Arai Y, Lencioni R et al (2016) Treatment of liver tumors with Lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Intervent Radiol 39(3):334–343
doi: 10.1007/s00270-015-1208-y
Das A, Gabr A, O'Brian DP et al (2019) Contemporary systematic review of health-related quality of life outcomes in locoregional therapies for hepatocellular carcinoma. J Vasc Interv Radiol 30(12):1924–33.e2
doi: 10.1016/j.jvir.2019.07.020
Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391(10127):1301–1314
doi: 10.1016/S0140-6736(18)30010-2
Kanematsu T, Furuta T, Takenaka K et al (1989) A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 10(1):98–102
doi: 10.1002/hep.1840100119
Park C, Choi SI, Kim H, Yoo HS, Lee YB (1990) Distribution of Lipiodol in hepatocellular carcinoma. Liver 10(2):72–78
doi: 10.1111/j.1600-0676.1990.tb00439.x
de Baere T, Dufaux J, Roche A et al (1995) Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology 194(1):165–170
doi: 10.1148/radiology.194.1.7997545
Idee JM, Guiu B (2013) Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol 88(3):530–549
doi: 10.1016/j.critrevonc.2013.07.003
Raoul JL, Heresbach D, Bretagne JF et al (1992) Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70(3):585–590
doi: 10.1002/1097-0142(19920801)70:3<585::AID-CNCR2820700308>3.0.CO;2-#
Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3):474–481
doi: 10.1016/j.jhep.2006.10.020
Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52
doi: 10.1007/s00270-009-9711-7
Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111(2):255–264
doi: 10.1038/bjc.2014.199
Georgiades CS, Hong K, D’Angelo M, Geschwind JF (2005) Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 16(12):1653–1659
doi: 10.1097/01.RVI.0000182185.47500.7A
Geschwind JF, Ramsey DE, Cleffken B et al (2003) Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 26(2):111–117
doi: 10.1007/s00270-002-2524-6
Favelier S, Germain T, Genson PY et al (2015) Anatomy of liver arteries for interventional radiology. Diagn Interv Imaging 96(6):537–546
doi: 10.1016/j.diii.2013.12.001
Chapiro J, Wood LD, Lin M et al (2014) Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology 273:746–758. https://doi.org/10.1148/radiol.14140033
doi: 10.1148/radiol.14140033
pubmed: 25028783
pmcid: 4263418
Chapiro J, Duran R, Lin M et al (2014) Identifying staging markers for hepatocellular carcinoma before transarterial chemoembolization: comparison of three-dimensional quantitative versus non-three-dimensional imaging markers. Radiology 275:438–447. https://doi.org/10.1148/radiol.14141180
doi: 10.1148/radiol.14141180
pubmed: 25531387
pmcid: 4409467
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216
doi: 10.1093/jnci/92.3.205
Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60
doi: 10.1055/s-0030-1247132
Avants BBT, Nicholas J, Johnson HJ. Advanced normalization tools. http://stnava.github.io/ANTs . Accessed 2019
Wang X, Yarmohammadi H, Cao G et al (2017) Dual phase cone-beam computed tomography in detecting <3 cm hepatocellular carcinomas during transarterial chemoembolization. J Cancer Res Ther 13(1):38–43
doi: 10.4103/0973-1482.206242
Wang Z, Chen R, Duran R et al (2015) Intraprocedural 3D quantification of lipiodol deposition on cone-beam CT predicts tumor response after transarterial chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 38(6):1548–1556
doi: 10.1007/s00270-015-1129-9
Hu J, Maybody M, Cao G et al (2016) Lipiodol retention pattern assessed by cone beam computed tomography during conventional transarterial chemoembolization of hepatocellular carcinoma: accuracy and correlation with response. Cancer Imaging 16(1):32
doi: 10.1186/s40644-016-0090-4
Matsui O, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Demachi H (1994) Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol 33(Suppl):S84–S88
doi: 10.1007/BF00686674
Schaupp CM, White CC, Merrill GF, Kavanagh TJ (2015) Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: a potential role for carbonyl reductase 3. Chem Biol Interact 234:154–161
doi: 10.1016/j.cbi.2014.11.010
Cusack BJ, Young SP, Driskell J, Olson RD (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32(1):53–58
doi: 10.1007/BF00685876
Del Tacca M, Danesi R, Ducci M, Bernardini C, Romanini A (1985) Might adriamycinol contribute to adriamycin-induced cardiotoxicity? Pharmacol Res Commun 17(11):1073–1084
doi: 10.1016/0031-6989(85)90113-4
Boucek RJ, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 262(33):15851–15856
doi: 10.1016/S0021-9258(18)47666-1
Chebib I, Shabani-Rad MT, Chow MS, Zhang J, Gao ZH (2007) Microvessel density and clinicopathologic characteristics in hepatocellular carcinoma with and without cirrhosis. Biomark Insights 2:59–68
doi: 10.1177/117727190700200013
Wang Q, Koniaris LG, Milgrom DP et al (2019) CT and MRI imaging and interpretation of hepatic arterioportal shunts. Transl Gastroenterol Hepatol 4:34
doi: 10.21037/tgh.2019.05.05
Chen CS, Li FK, Guo CY et al (2016) Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Oncotarget 7(6):7241–7252
doi: 10.18632/oncotarget.6892
Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M et al (2018) Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. Eur Radiol 28(7):3032–3040
doi: 10.1007/s00330-017-5198-9
Yang Z, Zou R, Zheng Y et al (2019) Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation. Eur Radiol 29(11):5752–5762
doi: 10.1007/s00330-019-06157-0
van Breugel JMM, Geschwind JF, Mirpour S et al (2019) Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. Theranostics 9(13):3674–3686
doi: 10.7150/thno.32943
Miszczuk MA, Chapiro J, Geschwind JH et al (2019) Lipiodol as an imaging biomarker of tumor response after conventional transarterial chemoembolization: prospective clinical validation in patients with primary and secondary liver cancer. Transl Oncol 13(3):100742
doi: 10.1016/j.tranon.2020.01.003
Malagari K, Pomoni M, Moschouris H et al (2014) Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 mum. Safety and efficacy study. Cardiovasc Intervent Radiol 37(1):165–175
doi: 10.1007/s00270-013-0777-x
van Malenstein H, Maleux G, Vandecaveye V et al (2011) A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 34(7):368–376
doi: 10.1159/000329602